New NCI SBIR Funding Opportunity Available: Innovative Molecular Analysis Technology Development for Cancer Research and Clinical Care

Upcoming Opportunity for Companies Developing Innovative Technologies that Improve Molecular and Cellular Analysis of Cancer

Next Deadline: November 4, 2013

NCI SBIR Funding Opportunity: Innovative Molecular Analysis Technology Development for Cancer Research and Clinical Care (PAR-13-327)

Upcoming Receipt Date: November 4, 2013

The National Cancer Institute (NCI) announces the availability of a funding opportunity aimed at accelerating the development and commercialization of highly innovative technologies that improve molecular and/or cellular analysis of cancer with a significant likelihood for either overcoming persistent challenges or obstacles or opening entirely new fields for cancer research or clinical care. This Program Announcement complements the goals of the NCI’s Innovative Molecular Analysis Technologies (IMAT) program by facilitating a path towards technology commercialization. Prior participation in the IMAT Program is not required for eligibility for this FOA. Applications are expected to indicate the significant attributes and advantages of the proposed technology over currently available technologies and conventional approaches.

The NCI is interested in supporting the commercial development of emerging molecular and/or cellular analytical technologies intended for cancer detection and/or characterization. Technology areas of interest include, but are not limited to, the following:

  • Technologies capable of deciphering basic mechanisms underlying cancer initiation and progression;
  • Technologies that enable substantially-improved early cancer detection and/or cancer risk assessment;
  • Technologies capable of distinguishing, assessing, and/or monitoring cancer stage, and progression;
  • Technologies to facilitate/accelerate the processes of drug discovery or development of generic approaches to improve drug delivery;
  • Technologies that can facilitate and/or enhance molecular analyses in cancer epidemiology (e.g., by allowing for rigorous and/or expeditious collection of various relevant types of data);
  • Technologies for sample preparation and/or processing for improved downstream analysis;
  • Technologies that offer a novel means for assessing general analyte quality to determine sample fitness-for-purpose for a known analytical platform; and
  • Technologies or tools that may help overcome various barriers in research on the incidence, prevalence, mortality, and burden of cancer among members of underserved populations.

A non-exclusive list of product examples relevant to this funding opportunity are available at:

To view the full FOA, please visit:

PA-13-327, Innovative Molecular Analysis Technology Development for Cancer Research and Clinical Care (R43/R44)
Next receipt date: November 4, 2013

A pre-application webinar will be held on September 17, 2013. If interested in attending please click here to register.

For more information, please contact:

Amir Rahbar, PhD, MBA
National Cancer Institute (NCI)
Telephone: 240-276-5230


The SBIR & STTR Programs are NCI’s engine of innovation for developing and commercializing novel technologies and products to prevent, diagnose, and treat cancer. The SBIR & STTR Programs are government set-aside programs for domestic small businesses to engage in research and development that has the potential for commercialization and public benefit.

Sign up to receive updates about
SBIR & STTR funding opportunities at


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: